
Terumo Corporation
4543.TJPXHealthcareMedical - Instruments & Supplies
最新資料
¥2,595.5
+¥26.50 · +1.03%
4543.T公司概覽
盤中時間採用JST。市場資料可能有所延遲。
公司概況
公司網站Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
- 產業
- Medical - Instruments & Supplies
- 部門
- Healthcare
- 總部
- JP
- 執行長
- Hikaru Samejima
- 上市以來
- 1982年6月20日
- 僱員
- 31,185
市場位置
52週區間
目前¥2,595.5,
- 開盤價
- ¥2,595.5
- 前收盤價
- ¥2,569
- 成交量
- 0
- 0× 平均值
- 平均成交量
- 536.37萬
- 日均成交量
- 市值
- 3.83兆 JPY
- 貝塔
- 0.23
- 市場參考 1
- 50天平均值
- ¥2,310.22
- 高於平均水平+12.35%
- 200天平均值
- ¥2,220.43
- 高於平均水平+16.89%
財務數據
財務快照
最近十二個月估值與收益率
- 本益比(TTM)
- 23.28×
- 股價淨值比(TTM)
- 2.3×
- 股價營收比(TTM)
- 3.23×
- 股息率
- 1.16%
獲利能力和效率
- 毛利率
- 53.03%
- 營業利益率
- 16.90%
- 淨利潤率
- 13.90%
財務健康
- 負債權益比
- 0.23×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(JPY) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.13兆 JPY | 1.04兆 JPY | 9218.63億 JPY | 8202.09億 JPY | 7033.03億 JPY |
| 銷貨成本 | 5372.01億 JPY | 5033.92億 JPY | 4676.9億 JPY | 4263.71億 JPY | 3545.57億 JPY |
| 毛利 | 5946.76億 JPY | 5327.79億 JPY | 4541.73億 JPY | 3938.38億 JPY | 3487.46億 JPY |
| 研究與開發 | — | 742.24億 JPY | 690.6億 JPY | 615.83億 JPY | 518.37億 JPY |
| 銷售、一般及管理費用 | 4099.37億 JPY | 2795.33億 JPY | 2509.17億 JPY | 2149.21億 JPY | 1787.88億 JPY |
| 營業費用 | 4099.37億 JPY | 3537.57億 JPY | 3199.77億 JPY | 2765.04億 JPY | 2306.25億 JPY |
| 利息收入 | 62.48億 JPY | 33.6億 JPY | 24.11億 JPY | 14.71億 JPY | 5.1億 JPY |
| 利息支出 | 32.86億 JPY | 20.16億 JPY | 20.65億 JPY | 22.3億 JPY | 16.38億 JPY |
| 折舊和攤銷 | 953.79億 JPY | 854.49億 JPY | 767.45億 JPY | 702.38億 JPY | 588.82億 JPY |
| 營業利益 | 1847.39億 JPY | 1790.22億 JPY | 1341.96億 JPY | 1173.34億 JPY | 1181.21億 JPY |
| 淨利 | 1359.14億 JPY | 1169.78億 JPY | 1063.74億 JPY | 893.25億 JPY | 888.13億 JPY |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 73%
- 優於預期8次、低於預期3次、符合預期0次
- 平均EPS意外幅度
- +12.44%
- 11 類似報告
- 最新每股收益結果
- 47.74
- 預估25.18 · 優於預期89.59%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
股利和股票分割
公司行動歷史
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年3月28日 | 2:1 | — | — |
股票分割 | 2019年3月27日 | 2:1 | — | — |
股票分割 | 2014年3月27日 | 2:1 | — | — |
已生效 2024年3月28日
2:1
已生效 2019年3月27日
2:1
已生效 2014年3月27日
2:1
4543.T同業公司
持有4543.T的ETF
報告持有此股票曝險的交易所交易基金。
iShares Core Nikkei 225 ETF1329.T220.32億1.04%2.12兆 JPY0.05%¥6,789-0.77%
iShares Core TOPIX ETF1475.T86.91億0.30%2.89兆 JPY0.05%¥417.7-0.07%
iShares JPX-Nikkei 400 ETF1364.T25.52億0.43%5923.37億 JPY0.05%¥3,7610.00%
Vanguard Total International Stock ETFVXUS3.11億0.05%6462億 USD0.05%US$87.20-0.58%
Vanguard FTSE Developed Markets ETFVEA2.07億0.06%3150億 USD0.03%US$73.06-0.49%
iShares Core MSCI EAFE ETFIEFA1.59億0.08%1951.41億 USD0.07%US$100.67-0.18%
iShares MSCI Japan ETFEWJ9270.31萬0.41%224.93億 USD0.49%US$94.84-0.36%
JPMorgan BetaBuilders Japan ETFBBJP8164.43萬0.43%189.57億 USD0.19%US$76.60-0.35%
iShares Core Nikkei 225 ETF1329.T- 市場價值
- 220.32億
- 重量
- 1.04%
- AUM
- 2.12兆 JPY
- 費用率
- 0.05%
- 價格 / 1日
- ¥6,789-0.77%
iShares Core TOPIX ETF1475.T- 市場價值
- 86.91億
- 重量
- 0.30%
- AUM
- 2.89兆 JPY
- 費用率
- 0.05%
- 價格 / 1日
- ¥417.7-0.07%
iShares JPX-Nikkei 400 ETF1364.T- 市場價值
- 25.52億
- 重量
- 0.43%
- AUM
- 5923.37億 JPY
- 費用率
- 0.05%
- 價格 / 1日
- ¥3,7610.00%
Vanguard Total International Stock ETFVXUS- 市場價值
- 3.11億
- 重量
- 0.05%
- AUM
- 6462億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$87.20-0.58%
Vanguard FTSE Developed Markets ETFVEA- 市場價值
- 2.07億
- 重量
- 0.06%
- AUM
- 3150億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$73.06-0.49%
iShares Core MSCI EAFE ETFIEFA- 市場價值
- 1.59億
- 重量
- 0.08%
- AUM
- 1951.41億 USD
- 費用率
- 0.07%
- 價格 / 1日
- US$100.67-0.18%
iShares MSCI Japan ETFEWJ- 市場價值
- 9270.31萬
- 重量
- 0.41%
- AUM
- 224.93億 USD
- 費用率
- 0.49%
- 價格 / 1日
- US$94.84-0.36%
JPMorgan BetaBuilders Japan ETFBBJP- 市場價值
- 8164.43萬
- 重量
- 0.43%
- AUM
- 189.57億 USD
- 費用率
- 0.19%
- 價格 / 1日
- US$76.60-0.35%
繼續GoAI的研究
在 GoAI 中研究4543.Tresearch.disclaimer





